Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
March 25 2014 - 6:00AM
Marketwired
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment
for Psoriasis
BEVERLY, MA--(Marketwired - Mar 25, 2014) - Cellceutix
Corporation (OTCQB: CTIX) (the "Company"), a clinical stage
biopharmaceutical company developing innovative therapies in
oncology, dermatology, and antibiotic applications, is pleased to
announce the initiation of the Company's clinical trial of its
oral, small molecule drug candidate Prurisol™ for the treatment of
psoriasis. The Prurisol™ tablets have been delivered to the
clinical site in Miami, Florida and screening of subjects can now
begin with the first dosing expected in the coming days.
Cellceutix has reported the initiation of the study to the
www.clinicaltrials.gov website and expects the updates to be
reflected soon.
"We are excited to now have three clinical trials ongoing for
our portfolio of drug candidates," commented Dr. Krishna Menon,
Chief Scientific Officer at Cellceutix. "Not only is there no
cure for psoriasis, but the biologics that are so commonly used
today have been shown to frequently become ineffective in a
relatively short period of time, leaving a tremendous market
opportunity for a new drug. Being that Prurisol is a small
molecule, it is less likely that the body will develop antidrug
antibodies, as it does with biologics to stifle their
efficacy. The preclinical data showing that Prurisol
essentially eliminated all traces of psoriasis without signs of
recurrence leaves us extremely optimistic about the potential of
the compound as it enters human trials."
About Cellceutix: Headquartered in Beverly, Massachusetts,
Cellceutix is a publicly traded company under the symbol "CTIX".
Cellceutix is a clinical stage biopharmaceutical company developing
innovative therapies in oncology, dermatology and antibiotic
applications. Cellceutix believes it has a world-class portfolio of
compounds and is now engaged in advancing its compounds and seeking
strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is
currently in a Phase 1 clinical trial at Harvard Cancer Centers'
Dana Farber Cancer Institute and Beth Israel Deaconess Medical
Center. In the laboratory Kevetrin has shown to induce activation
of p53, often referred to as the "Guardian Angel Gene" due to its
crucial role in controlling cell mutations. Cellceutix is planning
a Phase 2 clinical trial with its novel compound Brilacidin-OM for
the prevention and treatment of Oral Mucositis. Brilacidin-OM, a
defensin mimetic compound, has shown in the laboratory to reduce
the occurrence of severe ulcerative oral mucositis by more than 94%
compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is
presently in a bioequivalence crossover clinical trial in Miami,
FL. Prurisol is a small molecule that acts through immune
modulation and PRINS reduction. Cellceutix's key antibiotic,
Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and
Skin Structure Infections, or ABSSSI. Brilacidin has the potential
to be a single-dose therapy or a dosing regimen that is shorter
than currently marketed antibiotics for multi-drug resistant
bacteria (Superbugs). Cellceutix has formed research collaborations
with world-renowned research institutions in the United States and
Europe, including MD Anderson Cancer Center, Beth Israel Deaconess
Medical Center, and the University of Bologna. More information is
available on the Cellceutix web site at www.cellceutix.com.
Forward-Looking Statements This press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
that involve risks, uncertainties and assumptions that could cause
Cellceutix's actual results and experience to differ materially
from anticipated results and expectations expressed in these
forward looking statements. Cellceutix has in some cases identified
forward-looking statements by using words such as "anticipates,"
"believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar
expressions. Among other factors that could cause actual results to
differ materially from those expressed in forward-looking
statements are Cellceutix's need for, and the availability of,
substantial capital in the future to fund its operations and
research and development; including the amount and timing of the
sale of shares of common stock to Aspire Capital; the fact that
Cellceutix's compounds may not successfully complete pre-clinical
or clinical testing, or be granted regulatory approval to be sold
and marketed in the United States or elsewhere. A more complete
description of these risk factors is included in Cellceutix's
filings with the Securities and Exchange Commission. You should not
place undue reliance on any forward-looking statements. Cellceutix
undertakes no obligation to release publicly the results of any
revisions to any such forward-looking statements that may be made
to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events,
except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich
(978) 236-8717 Email Contact
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Sep 2023 to Sep 2024